Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Osteoporosis Drug Stops Growth of Breast Cancer Cells, Even in Resistant Tumors

By BiotechDaily International staff writers
Posted on 03 Jul 2013
A drug approved in Europe to treat osteoporosis has now been shown to suppress the growth of breast cancer cells, even in cancers that have become resistant to current targeted therapies.

Presented on June 15, 2013, at the annual Endocrine Society meeting in San Francisco (CA, USA), the findings demonstrate that the drug bazedoxifene triggers a formidable one-two punch that not only blocks estrogen from promoting breast cancer-cell growth, but also targets the estrogen receptor for destruction.

“We found bazedoxifene binds to the estrogen receptor and interferes with its activity, but the surprising thing we then found was that it also degrades the receptor—it gets rid of it,” said senior author Donald McDonnell, PhD, chair of Duke Cancer Institute’s (Durham, NC, USA) department of pharmacology and cancer biology.

In animal and cell culture studies, the drug suppressed growth both in estrogen-dependent breast cancer cells and in cells that had developed resistance to the antiestrogen tamoxifen and/or to the aromatase inhibitors, two of the most widely used types of drugs to prevent and treat estrogen-dependent breast cancer. Currently, if breast cancer cells develop resistance to these therapies, patients are usually treated with toxic chemotherapy agents that have significant side effects.

Bazedoxifene is an agent that, similar to tamoxifen, belongs to a class of drugs known as specific estrogen receptor modulators (SERMs). These drugs act like estrogen in some tissues, while substantially blocking estrogen action in other tissues. However, unlike tamoxifen, bazedoxifene has some of the characteristics of a newer group of drugs called selective estrogen receptor degraders (SERDs), which can target the estrogen receptor for destruction.

“Because the drug is removing the estrogen receptor as a target by degradation, it is less likely the cancer cell can develop a resistance mechanism because you are removing the target,” said lead author Suzanne Wardell, PhD, a research scientist working in McDonnell’s lab. Many researchers had presumed that once breast cancer cells developed resistance to tamoxifen; however, “We discovered that the estrogen receptor is still a good target, even after it resistance to tamoxifen has developed,” he said.

The investigators evaluated a range of breast cancer-cell types, including tamoxifen-sensitive cells that are resistant to the drug lapatinib; another targeted therapy that is used to treat patients with advanced breast cancer whose tumors contain the mutant HER2 gene. These cells had previously been shown to reactivate estrogen signaling in order to acquire drug resistance. In this cell type, bazedoxifene also strongly inhibited cell growth.

Ironically, in bone tissue, bazedoxifene mirrors the action of estrogen, helping protect it from destruction. Because bazedoxifene has already undergone safety and effectiveness studies as a treatment for osteoporosis, it may be a feasible near-term alternative for patients with advanced breast cancer whose tumors have become resistant to other treatment approaches, Dr. Wardell reported. In clinical trials, the most frequently reported side effect was hot flashes in the bazedoxifene treatment groups.

The study was funded by a research grant from Pfizer Pharmaceuticals (New York, NY, USA), maker of bazedoxifene.

Related Links:

Duke Cancer Institute





Channels

Genomics/Proteomics

view channel
Image: Many molecular biology studies begin with purified DNA and RNA extracted from complex environments such as the human gut (Photo courtesy of Los Alamos [US] National Laboratory).

New Metagenomics Analysis Tool Reduces False Discovery Rates

Genomic researchers recently described a novel new tool for analyzing the complex data generated during DNA screens of mixed populations of organisms such as the human gut microbiome. DNA screening... Read more

Biochemistry

view channel
Image:  Model depiction of a novel cellular mechanism by which regulation of cryptochromes Cry1 and Cry2 enables coordination of a protective transcriptional response to DNA damage caused by genotoxic stress (Photo courtesy of the journal eLife, March 2015, Papp SJ, Huber AL, et al.).

Two Proteins Critical for Circadian Cycles Protect Cells from Mutations

Scientists have discovered that two proteins critical for maintaining healthy day-night cycles also have an unexpected role in DNA repair and protecting cells against genetic mutations that could lead... Read more

Business

view channel

“Softer” Mass Spec Techniques Gain Advantage in Biomarker Discovery

Two mass spectrometry (MS) technologies, MALDI and DESI, are increasing in applications as their effectiveness is established, according to Kalorama Information (New York, NY, USA) in its report “Proteomics Markets for Research and IVD Applications (Mass Spectrometry, Chromatography, Microarrays, Electrophoresis, Immunoassays,... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.